On March 17, 2026 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) reported three of the Company’s internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC) for small cell lung cancer (SCLC); ZL-6201, a leucine-rich repeat-containing protein 15 (LRRC15) ADC for the treatment of sarcoma and epithelial tumors with LRRC15 expressing cancer-associated fibroblasts (CAFs); and, ZL-1222, a PD-1 and interleukin-12 (IL-12) signaling attenuated mutein agonist immunocytokine for cancer immunotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The breadth and profile of our global oncology pipeline, highlighted by zoci, ZL-6201, and ZL-1222, underscore our commitment to developing innovative therapies for cancers that remain difficult to treat with current standards of care," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "Leveraging our integrated U.S.-China development model, we are advancing these programs with speed and quality, and the data we will present at AACR (Free AACR Whitepaper) reinforces our confidence in these compounds."

Zoci targets DLL3, a validated therapeutic target for SCLC that is overexpressed in many neuroendocrine tumors and is generally associated with poor clinical outcomes. Zoci is on track to become Zai Lab’s first global oncology launch, with plans for three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026. Its potential best-in-class safety profile, coupled with compelling systemic and intracranial efficacy, supports its potential role as a new standard of care in previously treated ES-SCLC, as well as a backbone ADC in first line combination regimens, including those that reduce the burdens of chemotherapy. Studies with other combinations and lines of therapies are planned.

LRRC15 is a type I transmembrane protein and an appealing target for cancer therapy because it is overexpressed in various mesenchymal tumors, such as sarcoma, glioblastoma and melanoma, as well as in CAFs across many other tumor types. Zai Lab is evaluating ZL-6201 as a potential first-in-class LRRC15-targeting ADC for the treatment of multiple solid tumors.

Interleukin-12 treatments have shown potential therapeutic benefit across a range of cancer types; however, narrow therapeutic windows and toxicity concerns have limited the utility of this therapeutic class. Zai Lab is evaluating ZL-1222 as a potential next-generation PD-1 and attenuated IL-12 immunocytokine bispecific protein for cancer immunotherapy across multiple indications, potentially combining potent antitumor activity with improved systemic safety.

Details regarding the Zai Lab poster presentations at AACR (Free AACR Whitepaper) 2026 are as follows:

Title: Discovery of ZL-6201, a novel LRRC15-targeting antibody drug conjugate (ADC) for the treatment of sarcomas and epithelial solid tumors
Session Title: Antibodies, Antibody-Drug Conjugates, and Nucleic Acids
Date/Time: Monday, April 20, 2026, from 9:00 a.m. – 12:00 p.m. PT
Location: San Diego Convention Center, Poster Section 38
Poster Board Number: 7
Publish Abstract Number: 2399

Title: ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, overcomes PD-1 resistance and enhances antitumor immunity with an accepted safety profile
Session Title: Monoclonal Antibodies and Antibody-Cytokine Platforms
Date/Time: Tuesday, April 21, 2026, from 9:00 a.m. – 12:00 p.m. PT
Location: San Diego Convention Center, Poster Section 9
Poster Board Number: 2
Publish Abstract Number: 4331

Title: Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previously treated extensive-stage small cell lung cancer and baseline brain metastasis: Analysis of a phase 1 trial
Session Title: Phase 1 Clinical Trials
Date/Time: Tuesday, April 21, 2026, from 9:00 a.m. – 12:00 p.m. PT
Location: San Diego Convention Center, Poster Section 50
Poster Board Number: 15
Publish Abstract Number: CT193

Title: Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors
Session Title: Phase 1 Clinical Trials
Date/Time: Tuesday, April 21, 2026, from 9:00 a.m. – 12:00 p.m. PT
Location: San Diego Convention Center, Poster Section 50
Poster Board Number: 11
Publish Abstract Number: CT189

(Press release, Zai Laboratory, MAR 17, 2026, View Source [SID1234663645])

On March 17, 2026 Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, reported an upcoming poster presentation on their oral Kinesin degrader program at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, which is being held April 17 – 22, in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Boundless has identified a novel kinesin target ("Kinesin") essential to ecDNA segregation and inheritance in cancer cells, but non-essential in healthy cells. Boundless is developing BBI-940, a potentially first-in-class, oral, selective, Kinesin degrader, which is the subject of the ongoing first-in-human KOMODO-1 (Kinesin Oral Molecular Degrader for Oncology) clinical trial (NCT07408089) in patients with advanced or metastatic estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer or triple-negative breast cancer of the luminal androgen receptor subtype (TNBC-LAR).

Details of the presentation are as follows:

Title: Selective degradation of a novel kinesin as a potential therapeutic strategy addressing high-risk extrachromosomal DNA (ecDNA) positive cancers, including breast cancer
Abstract Presentation Number: LB361
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date and Time: Tuesday, April 21, 2026, 2:00 PM – 5:00 PM PT
Location: Poster Section 53
Poster Board Number: 18

(Press release, Boundless Bio, MAR 17, 2026, View Source [SID1234663661])

On March 17, 2026 Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated oncology delivery platform, reported it will deliver two presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place from 17 April 2026 to 22 April 2026 in San Diego, California, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the two presentations:

Title: AVA6103 is a FAP-enabled pre|CISION peptide-drug conjugate delivering sustained release of exatecan in the tumor microenvironment with potent antitumor activity

Authors: Curtis Rink, Tom Clough, Ellen Watts, Folake Orafidiya, Marine Houée, Sophie Brown, Victoria Juskaite, Gezim Lahu, Ruairidh Edwards, Karen Campbell, Dave Liebowitz, David Jones, Michelle Morrow, Francis Wilson

Poster number and Location: 5846, Section 17, Board 15
Session: Tumor Microenvironment, Multi-specifics, and Immunomodulation
Section: Experimental and Molecular Therapeutics
Timing: Tuesday, 21 April 2026, 2:00-5:00pm PDT

Title: Characterization and translational development of novel pre|CISION technology compounds delivering complementary dual payloads to the tumor microenvironment following FAP cleavage

Authors: Victoria Juskaite, Tom Clough, Ellen Watts , Alexa Kennedy, Iva Zlatareva, Folake Orafidiya, Hanna Buist, Jannah Jeon, Greg Billenness, Douglas Sammon, Sophie Brown, Curtis Rink , Ruairidh Edwards, Vidicha Chunilal, Manuel Pinto, Dave Liebowitz, Francis Wilson, Michelle Morrow, David Jones

Poster number and Location: 5656, Section 10, Board 26
Session: Antibody-Drug Conjugates and Linker Engineering 4
Section: Experimental and Molecular Therapeutics
Timing: Tuesday 21 April 2026, 2:00-5:00pm PDT

(Press release, Avacta Life Sciences, MAR 17, 2026, View Source [SID1234663678])

On March 17, 2026 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, reported a preliminary update showing a continued reduction in the recurrence rate in the fully enrolled, 250 patient, open label non-HLA-A*02 arm of FLAMINGO-01.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

6 Months of Additional Patient Data Since Last Update Shows Recurrence Rate of <1% per Year in Non-HLA-A*02 Patients Treated with GLSI-100, Following Completion of Primary Immunization Series (PIS)

This <1% Annual Recurrence Rate Observed in Non-HLA-A*02 Patients is Statistically Significantly Smaller Than a 4% Annual Recurrence Rate Over a Similar Time Period Observed in the Katherine Study (Kadcyla Treated Arm) Yielding an Approximately 70-80% Reduction in Recurrence Rate as Explained Below
The non-HLA-A*02 arm does not have a direct placebo comparator arm, thus a Kaplan Meier survival analysis is not possible, and the following method was used:

The <1% recurrence rate per year of these 250 treated patients after completing the PIS was compared to the expected historical recurrence rate per year reported for a similar population in the Katherine study who received TDM1 (Kadcyla), which is about 4% recurrences per year or higher in the initial years of the Katherine study. The majority of the treated patients in FLAMINGO-01 also received TDM1 followed by GLSI-100.

As of this data cut, the current recurrence rate of the non-HLA-A*02 patients treated with GLSI-100, following completion of the PIS over an average of 1.2 years of patient exposure, is statistically significantly smaller than a 4% annual recurrence rate over a similar time period observed in the Katherine study (0.7% versus 4% annual recurrence rate over 1.2 patient-years, 83% reduction in recurrence rate, Chi Square, p < 0.005). This preliminary data will continue to be updated and cleaned, so future and final results may vary. Future updates may be presented at upcoming conferences.
This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
Additional information about the non-HLA-A*02 arm follows:

Virtually all of the non-HLA-A*02 patients have completed the primary immunization series, which is the first 6 monthly vaccinations in the study.

Every 6 months approximately 110 patient-years are added to the non-HLA-A*02 patient data base.

Enhertu (T-DXd) treated patients can be enrolled in FLAMINGO-01. In the future, if Enhertu is approved for high risk patients in the adjuvant setting, more Enhertu treated patients could be enrolled in FLAMINGO-01 and may recur at a lower rate than if treated with Kadcyla. The recurrence rate assumptions in the design of FLAMINGO-01 include this possibility as well as other potential improvements in standard of care.
Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.

About FLAMINGO-01 Open Label Phase III Data

More than 1,000 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.

In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed compared to the recurrence rates comparable to those observed in the Katherine study of Kadcyla shows an approximately 70-80% reduction in recurrence rate.
This non-HLA-A*02 arm observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.

About GLSI-100 Phase IIb Study

In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in cancer recurrences in the HER2/neu 3+ patients who were treated with GLSI-100, followed, and remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb results can be summarized as follows:

80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.

The PIS elicited a potent immune response as measured by local skin tests and immunological assays.
About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.

For more information on FLAMINGO-01, please visit the Company’s website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: [email protected]

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

(Press release, Greenwich LifeSciences, MAR 17, 2026, View Source [SID1234663613])

On March 17, 2026 Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a biotechnology company pioneering the field of degrader antibody conjugates (DACs), reported that new preclinical data on ORM-1153, a CD123-targeting DAC designed to selectively deliver a proprietary GSPT1-degrading payload for the treatment of acute myeloid leukemia (AML), will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22 in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Orum’s two posters on ORM-1153 will highlight preclinical efficacy, pharmacology, and non-human primate safety findings that support advancement toward clinical development in AML.

"The data being presented at AACR (Free AACR Whitepaper) reflect continued progress for ORM-1153 and Orum’s Dual-Precision TPD² approach," said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. "These preclinical data, including repeat-dose non-human primate studies, support advancement toward clinical development and underscore the potential of our approach to expand the therapeutic window beyond conventional cytotoxic antibody-drug conjugates."

Orum’s AACR (Free AACR Whitepaper) 2026 Presentation Details
Both posters will be presented on Monday, April 20, from 9 am to 12 pm PDT.

ORM-1153: A Novel CD123-Targeting Degrader Antibody Conjugate with Proprietary GSPT1 Degrading Payload for the Treatment of Acute Myeloid Leukemia
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Drug Conjugates and Linker Engineering 2
Location: Poster Section 13
Poster Board Number: 7
Poster Number: 1710

ORM-1153: A Next-Generation CD123-Targeting Degrader Antibody Conjugate (DAC)
Session Category: Experimental and Molecular Therapeutics
Session Title: Quantitative Pharmacology and Translational Modeling
Location: Poster Section 17
Poster Board Number: 12
Poster Number: 1824
Posters will be available on Orum’s website following the presentation.

About ORM-1153

ORM-1153 is a CD123-targeting degrader antibody conjugate developed using Orum’s Dual-Precision TPD² approach. The molecule conjugates a proprietary GSPT1-degrading payload to an anti-CD123 antibody with high internalization efficiency via a β-glucuronide cleavable linker. By combining tumor-selective antibody delivery with targeted protein degradation, ORM-1153 is designed to induce cancer cell death through degradation of GSPT1, a protein implicated in cell survival, including in TP53-mutant AML, while minimizing effects on normal tissues.

About Orum’s TPD² Approach

Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.

(Press release, Orum Therapeutics, MAR 17, 2026, View Source [SID1234663646])